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Treatment of Streptococcal Endocarditis with a Single Daily Dose of Ceftriaxone
and Netilmicin for 14 Days: A Prospective Multicenter Study
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From the Centre Hospitalier Universitaire Vaudois, Lausanne;
Hoffmann-La Roche, Basel, Switzerland; and Sanatorio Gilemes,
Buenos Aires, Argentina
A 2-week course of ceftriaxone (2 g) plus netilmicin (4 mglkg), administered as one short daily
iv infusion, was evaluated for the treatment of streptococcal endocarditis in an open multicenter
study. Of the 52 patients, 31 were infected with viridans streptococci, 18 with Streptococcus bovis,
two with Gemella morbillorum, and one with group C Streptococcus; 48 patients were assessable.
Infection was cured in 42 cases, 35 treated medically and seven treated both medically and surgically.
Five patients died without evidence of active infection, and one relapsed. The bacteriologic failure
was due to a strain of G. morbillorum against which no synergy of ceftriaxone and netilmicin was
evident in vitro. The serum creatinine level increased during treatment in four cases, all involving
patients >65 years old who had renal risk factors; in two of these cases, values did not return to
baseline during follow-up. Of 40 patients assessed for auditory function, only one developed de-
creased perception of borderline significance. Other adverse reactions were mild. This regimen was
efficacious, safe, and cost-effective for the treatment of streptococcal endocarditis. However, it must
be used with caution for patients with preexisting renal impairment or concomitant exposure to
other potentially nephrotoxic agents.
Four weeks of treatment with iv penicillin alone or 2 weeks
oftreatment with iv penicillin plus an aminoglycoside are effec-
tive for streptococcal endocarditis [1, 2]. However, such regi-
mens require several daily injections, and the use of aminogly-
cosides carries a risk of renal toxicity and ototoxicity [2, 3].
Two recent developments may allow more convenient and safer
treatment ofthis condition. First, a single daily dose ofceftriax-
one (a cephalosporin with a prolonged serum half-life) given
for 4 weeks has been found to be effective against streptococcal
endocarditis [4, 5]. This regimen has been used successfully
on an outpatient basis and without a permanent iv catheter.
Second, recent experimental and clinical evidence has sug-
gested that administration of the total daily dose of an amino-
glycoside in a single injection is as effective as administration
of the same amount of drug in two or three injections and
causes equal or less toxicity [6-9]. Indeed, in the treatment of
experimental streptococcal endocarditis, when given in a single
daily dose rather than as multiple doses, aminoglycosides were
just as synergistic with ,B-Iactam agents such as penicillin and
ceftriaxone [10-13].
The purpose of the multicenter study reported herein was to
test prospectively the efficacy and safety of a 2-week course of
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therapy for streptococcal (nonenterococcal) endocarditis with a
regimen consisting of ceftriaxone plus netilmicin given once a
day. The study was noncomparative since streptococcal endo-
carditis is a rare disease and the outcome of treatment with
penicillin is well known. The efficacy of penicillin is so high
that it would have been impossible to recruit enough patients
to exclude a type II error.
Patients and Methods
Adults with ceftriaxone-susceptible streptococcal native-
valve endocarditis were eligible for the study. The diagnostic
criteria for endocarditis were persistent bacteremia (i.e., at least
three sets of positive blood cultures, with samples drawn at
intervals of at least 30 minutes) plus (1) a new or changing
heart-valve regurgitation murmur and/or (2) a predisposing
heart disease associated with vascular phenomena and/or with
cardiac vegetations visualized by transthoracic echocardiogra-
phy [14]. The newly described criteria for the diagnosis of
endocarditis were also applied retrospectively [15].
Patients were excluded if they met any of the following
criteria: (1) antibiotic treatment for >48 hours before enroll-
ment; (2) hypersensitivity to cephalosporins or aminoglyco-
sides; (3) impairment of renal function, with serum creatinine
values at least 30% above the normal limit; or (4) clinically
apparent inner-ear or vestibular dysfunction. Ceftriaxone so-
dium and netilmicin were administered for 14 days at daily
doses of2 g and 4 mg/kg, respectively. Ceftriaxone was diluted
in 50 mL of 5% glucose and netilmicin in a similar volume of
0.9% NaCl. Both drugs were infused iv; the infusions lasted
30 and 60 minutes, respectively.
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Table 1. Outcome of 52 cases of streptococcal endocarditis treated
with a 2-week course of ceftriaxone (2 g) and netilmicin (4 mg/kg)
administered in a single daily dose.
* No evidence of active infection.
t Sterile blood culture at 3 months (35 cases) and/or sterile cardiac valves
at surgery or autopsy (7 cases).
~ No clinical evidence of disease at 3 and 6 months, respectively.
§ Infection due to Gemella morhillorum.
with antibiotics unrelated to the study drugs. The regimen was
switched to ceftriaxone plus netilmicin as soon as the results
of blood culture became available.
Table I summarizes the clinical and bacteriologic outcome
of the 52 cases. Four patients (8%) could not be fully assessed
for the following reasons. The first completed treatment but
did not return for follow-up and could not be located. The
second received ceftriaxone for a total of 35 days because of
a suspected concomitant hip-joint infection; his infection was
cured clinically and bacteriologically. The third and fourth pa-
tients discontinued treatment prematurely: the regimen was
changed to penicillin because of worsening renal function in
one case (on day 4) and to penicillin and gentamicin because
of the suspicion of rheumatic fever in the other (on day 8).
Of the 48 clinically assessable cases, 42 were cured-35
with antibiotic treatment alone and seven with combined antibi-
otic and surgical therapy. One patient relapsed (see below).
Five patients died. Two of the deaths occurred within a few
hours after valve replacement (on days 14 and 27, respectively),
and in these cases the valves as well as the blood cultured on
the same day were sterile. Another two deaths (on days 25 and
26, respectively) were related to the progression of heart failure
due to valvular insufficiency that could not be alleviated by
surgery; both of the patients involved already had signs of heart
failure while receiving antibiotic treatment. No autopsy was
conducted in these two cases, but no clinical evidence of active
infection was found and cultures of blood obtained on days 16
and 19, respectively, were sterile. The fifth death occurred
suddenly on day 62, 36 hours after a colostomy performed for
the resection of an adenoma; no autopsy was performed. In
Microbiological tests included cultures of blood and of other
potentially infected sites. Bacterial isolates were identified with
the API 20 Strep System (biolvlerieux, Marcy 1'Etoile, France).
Antibiotic susceptibility was assessed both by the Kirby-Bauer
method and by the determination of MICs with a standard
macrotube dilution technique.
Patients were evaluated daily during hospitalization as well
as once at the end of treatment, once between 2 and 4 weeks
after the completion of treatment, and once between 2 and 3
months after the end of therapy. Hematologic and chemical
analyses of blood and blood cultures, as well as urinalysis,
were undertaken before, during, and after treatment. Echocardi-
ography and audiometry were performed at the beginning and
end of treatment. Serum levels of netilmicin were determined
twice a week during treatment, both immediately before and
30 minutes after the end of infusion.
An infection was considered clinically cured if the patient
had no signs or symptoms suggestive of infection 3 months
after the completion of therapy. Bacteriologic cure was defined
by sterile blood cultures 3 months after therapy or by sterile
cardiac valves at surgery or autopsy.
Informed consent was obtained in all cases. The study was
approved by the ethical committees of the participating centers.
Results
A total of 52 patients (11 females and 41 males) were in-
cluded in the study. When the new criteria for the diagnosis
of endocarditis were applied retrospectively (and, in most cases,
without transesophageal echocardiography), 47 patients were
categorized as definite cases and five as probable cases. The
patients' median age was 61 years (range, 18-80 years). Thirty
patients had a known underlying valvular or congenital cardiac
abnormality. Mitral-valve infection was documented in 23
cases (44%); aortic infection in 18 cases (35%); combined
mitral and aortic infection in 10 cases (19%); and combined
mitral, aortic, and tricuspid infection in one case (2%). Twenty-
one patients had definite vegetations visualized by echocardiog-
raphy.
The bacteria isolated from blood were Streptococcus bovis
in 18 cases (35%), Streptococcus sanguis in 14 cases (27%),
Streptococcus mutans in six cases (12%), nongroupable viri-
dans streptococci in five cases (10%), Streptococcus milleri
and Streptococcus mitis in three cases each (6%), Gemella
morbillorum in two cases (4%), and group C Streptococcus in
one case (2%). None of the patients had another potential
source of persistent bacteremia. All strains were susceptible to
penicillin and ceftriaxone in the disk diffusion test. MICs were
determined for 47 of the 52 strains. The MIC90 was 0.25
j.Lg/mL (range, 0.016-0.5 j.Lg/mL) for ceftriaxone and penicillin
and 2 j.Lg/mL (range, 0.03-8 j.Lg/mL) for netilmicin.
After the drawing of blood cultures, 14 patients (27%) had
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this case the last blood sample cultured was obtained on day
22 and was sterile. The patient had no signs or symptoms of
active infection during the follow-up period.
A total of 43 cases were fully assessable bacteriologically;
infection was cured in 42 cases (98%). Two additional infec-
tions were considered presumably cured bacteriologically (ac-
cording to recent guidelines for trials of antibiotic treatment
for endocarditis [14]) since the patients were well at 3 and 6
months, respectively. However, these patients had moved
abroad and could not return for follow-up blood cultures.
One relapse was documented in a 49-year-old male. Two
months before admission, he had undergone dental treatment.
Two weeks later, he had developed fever without other symp-
toms. At the time ofhis admission, two-dimensional echocardi-
ography disclosed mitral-valve prolapse without insufficiency
and no visible vegetations. Blood cultures yielded a Streptococ-
cus-like microorganism that was later identified as G. morbi/-
forum. Three weeks after the completion of an uneventful
course of antibiotic treatment lasting 15 days, fever recurred
and blood cultures yielded the same microorganism. For both
strains, the MIC of ceftriaxone was 0.25 j.tg/mL and that of
netilmicin was 0.5 j.tg/mL. The patient was successfully treated
with a 4-week course of antibiotics: ceftriaxone (days 1-14),
amoxicillin (days 15- 28), and netilmicin (days 1-20). Time-
kill kinetics evaluated later showed tolerance to ceftriaxone
and an absence of synergy between ceftriaxone and netilmicin.
Nine patients underwent a total of 12 valve replacements
either during the treatment period (days 11, 13, and 14, respec-
tively) or during follow-up. The indication for surgery in all
cases was valvular incompetence. In seven cases the valves
were cultured and were sterile. In the two cases in which valves
were not cultured, cultures of blood obtained during follow-
up and before valve replacement were sterile.
A total of 19 adverse events related or possibly related to
antibiotic treatment were documented in 18 cases (35%). The
serum creatinine level increased during therapy in four cases,
all involving patients >65 years old; baseline values had been
elevated in two ofthese cases. In all four cases at least one other
contributing factor was identified (congestive cardiac failure in
two cases, diabetes in one case, hypertension in two cases, and
concomitant treatment with another nephrotoxic medication in
three cases), and in one case an overdose of netilmicin was
inadvertently administered. The dosage of netilmicin was ad-
justed in all four cases.
During follow-up, the serum creatinine level remained ele-
vated in two cases and returned to near-baseline values in the
other two. A slightly abnormal creatinine value was noted on
a single occasion during the follow-up period in two additional
instances. A transient twofold increase in transaminase values
was documented in three cases and candidal stomatitis in one
case. Five patients developed transient adverse reactions that
resolved without the interruption of therapy: there was one
case each of diarrhea (a 2-day episode), macular rash, flushing
ofthe face during drug infusion, shivering during drug infusion,
and pruritus. Forty patients had audiometry performed at base-
line and at the end of treatment; a 27-year-old male had a
unilateral20-decibel (15%) decrease in both aerial and osseous
perception of high-frequency sounds. (A decrease of > 15%
is considered significant.) Three patients developed catheter-
related phlebitis.
The peak and trough levels (mean ± SD) of netilmicin in
serum were 10.57 ± 4.59 j.tg/mL and 0.89 ± 0.76 j.tg/mL,
respectively. No drug accumulation was detected during treat-
ment.
Twenty-five patients were treated without indwelling cathe-
ters. Antibiotics were administered daily to these patients
through the placement of a butterfly needle. Twenty patients
received the antibiotics through a small peripheral catheter,
with or without a heparin lock between infusions. Three pa-
tients had a central venous line, and the mode of administration
was not recorded for four cases. Five patients were treated
solely as outpatients and 10 as both inpatients and outpatients.
Of the total of 672 days of antibiotic therapy for the 48 assess-
able patients, 124 were outpatient days.
Discussion
In the present study, we tested the efficacy and safety of
once-daily administration of ceftriaxone plus netilmicin in the
treatment of streptococcal endocarditis. This regimen was se-
lected because ofthe pharmacokinetic properties of ceftriaxone
[16] and the recent suggestions that a single daily injection of
an aminoglycoside is just as efficacious as and possibly less
toxic than multiple injections of the same total daily dose [6-
13]. Of 48 assessable patients, 42 had their infections cured,
five died during the follow-up period (none with evidence of
active infection), and one relapsed.
Although this study was not comparative, the relapse rate
was not different from those reported after treatment with peni-
cillin or ceftriaxone alone for 4 weeks [I, 4, 5] or with penicillin
plus streptomycin for 2 weeks [2, 3]. The relapse was due to
a microorganism of a genus (Gemella) that is now recognized
as separate from Streptococcus and that has been implicated
in complicated endocarditis [4]. No synergy of ceftriaxone and
netilmicin against this organism was apparent in vitro, although
synergy between .B-lactam antibiotics and aminoglycosides is
observed with most if not all streptococcal strains [17].
The mortality rate among the patients in this study (l0%)
is not unexpected in viridans streptococcal endocarditis [I],
although rates have been lower in some recent studies [2, 4,
5]. Deaths were due to several causes: two were related to
immediate postoperative complications (in patients whose
valves were sterile), one occurred suddenly at 2 months in a
patient with no evidence of active infection, and two were due
to progressive heart failure (cardiac surgery was postponed
for nonmedical reasons). Although active infection was not
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excluded in the last two cases by culture at autopsy, the patients
responded clinically to antibiotic treatment, and blood cultures
were sterile 1 and 4 days after treatment - that is, 1 week
before death. Thus, although uncontrolled infection cannot be
totally ruled out in some fatal cases, it appears unlikely.
The most frequent and severe adverse event was an increase
in the creatinine serum level, which was recorded in four cases
(8%) during treatment. All four patients involved were elderly
and had other characteristics that may have contributed to renal
impairment. In two of these cases, creatinine values remained
elevated during the follow-up period. The implication is that,
in patients with renal risk factors, an antibiotic regimen that
does not include an aminoglycoside must be preferred. In a
prior study of 59 patients treated with ceftriaxone alone, none
experienced a deterioration of renal function during therapy
[4]. However, a 4-week course of monotherapy with ,B-Iactam
antibiotics is complicated by other, potentially severe side ef-
fects, such as neutropenia [4, 18].
Two aspects of our findings are of special interest. First, a
single daily injection of an aminoglycoside combined with
ceftriaxone was bactericidal to a degree that permitted a short
(2-week) course of therapy for streptococcal endocarditis. Al-
though it is not known whether ceftriaxone alone would yield
comparable results, penicillin administered alone for 2 weeks
has resulted in failure rates as high as 15% [19]. Since penicillin
and ceftriaxone exhibit similar in vitro activity against strepto-
cocci [4], it is likely that in vivo synergy accounts for the high
efficacy of the regimen used in the present study. It is remark-
able that these results were obtained despite the fact that the
single daily injection of the aminoglycoside did not produce
therapeutic levels of this drug in serum for 24 hours in most
cases. In this study we used netilmicin (4 mg/[kg· d[), but
experimental and clinical studies suggest that the results would
be similar with gentamicin or tobramycin (3 mg/[kg· dj) [6, 8,
11, 13].
In studies of experimental streptococcal endocarditis, a sin-
gle daily dose of an aminoglycoside in combination with peni-
cillin or ceftriaxone resulted in a degree of in vivo synergy
equal to that attained with multiple injections of the same total
daily dose [10-13]. Several clinical studies compared once-
daily to twice- or thrice-daily aminoglycoside administration,
mostly in combination with ,B-lactam antibiotics; the two regi-
mens were equally efficacious [6-9]. However, none of these
studies included patients with infections for which the superior-
ity of a combined regimen is as well established as it is in
endocarditis. Thus, the present study adds to the evidence that
the constant, simultaneous presence of therapeutic levels of
aminoglycosides and ,B-Iactam antibiotics is not required for
in vivo synergy against streptococci. This finding may also
apply to other bacteria but may not hold true for all and is
especially unlikely to extend to enterococci [20, 21].
Second, the antibiotic regimen administered in our study
represents a simplification compared with traditional treatment.
For many patients with streptococcal endocarditis, the need for
several daily injections of parenteral antibiotics is the main
reason for prolonged hospitalization, and recent efforts to im-
prove therapy have been directed at a shorter course (e.g., high
doses of penicillin combined with two or three daily injections
of an aminoglycoside for 2 weeks) [3] or at the administration
of the total daily dose in only one injection, obviating the
need for a permanent iv line and allowing partial or complete
outpatient treatment in some cases [4, 5]. These approaches
are not only more comfortable for the patient but also less
expensive [22]. Outpatient treatment of endocarditis is already
used in practice by many physicians [23]. In two studies of
therapy with ceftriaxone alone for 4 weeks or with ceftriaxone
for 2 weeks followed by oral amoxicillin for 2 weeks, outpatient
treatment was found to be effective and safe, provided that
patients were appropriately selected [4, 5]. With the regimen
used in our study, the burden of treatment can be further re-
duced, and some patients-once evaluated and stabilized in
the hospital-can be sent home and receive only a few addi-
tional days of outpatient treatment with one daily injection of
antibiotics.
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